Myriad hereditary cancer risk assessment program study now featured in the Obstetrics & Gynecology
Get started with MyRisk with RiskScore by downloading the provider product overview.
Download provider overviewBack
Order MyRisk
Resources
Interested in learning more about the MyRisk test and your ordering options? Fill out the form below to get started.
By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.
Contact Information
MyRisk® Hereditary Cancer Test evaluates 48 genes associated with hereditary cancer risk to identify genetic changes in patients with a family history of certain cancers, empowering healthcare providers to personalize care plans and help prevent cancer.
Make confident decisions with definitive answers from MyRisk.
For patients with a family history of certain cancers, hereditary cancer testing is essential to identify whether they are at an increased risk of developing specific types of cancer. 1 in 4 patients without cancer meet criteria for germline genetic testing.1
For people with a history of cancer, MyRisk identifies hereditary cancer syndromes associated with an increased risk of a second cancer, providing information to guide risk management decisions and facilitate family risk assessment.
1 in 4
women without cancer qualify for germline genetic testing1
MyRisk with RiskScore is a powerful tool that empowers you and your patients to make more informed decisions to help prevent breast cancer or diagnose it at an earlier, more treatable stage.
Myriad is the industry leader in variant classification and reclassification. We use proprietary variant classification tools, including RNA testing and other cutting-edge technology, to provide comprehensive, clinically actionable and accurate results.
MyRisk offers the industry’s lowest reported rates of BRCA1/2 variants of uncertain significance (VUS) of <1.0%.6,7
Myriad continuously re-evaluates VUS and sends amended reports whenever a patient’s result is reclassified a clinically significant.
Every MyRisk test report provides a personalized assessment of a patient’s hereditary cancer risk, providing healthcare providers and patients with clear information to make informed decisions about managing cancer risk.
MyRisk with RiskScore assesses patient risk beyond just positive or negative.
Positive result report Elevated result report Negative result report
The MyRisk Management Tool offers personalized guidance for patients with a higher risk of cancer. These plans may include guidelines for increased surveillance, risk- reducing medications, and/or risk-reducing surgery.
Eligible patients will be provided with a RiskScore which gives a personalized estimate of their five-year and remaining lifetime risk for developing breast cancer, guiding more confident decisions in managing their breast cancer risk.
Myriad offers several MyRisk ordering options to better serve your patients and your practice, including portals for online ordering and options for sending MyRisk test kits directly to your patients’ homes.
Myriad offers simplified workflow solutions that are customizable to your practice, saving staff time and reducing administrative burden.
Real expert support
First-class support from our team of board-certified genetic counselors gives you on-demand access to the information you need for every patient, every test, every time.
Workflows
Workflow solutions allow for simple integration of Myriad’s tests into routine clinical care and help patients better understand and benefit from their results.
MyRisk Patient Story
Lisa’s mom’s battle with breast cancer inspired her to get genetic testing and make a life-saving choice. Her story is a testament to courage and resilience.
With Myriad, you can receive comprehensive results for germline testing, tumor genomic profiling, and companion diagnostic options in one single ordering experience, getting clear, fast answers for your patients.
MyRisk offers clinically actionable results and personalized medical management guidance to inform confident patient care.
Myriad is committed to providing patients with access to accurate and affordable genetic results through extensive coverage with most insurance plans and financial assistance programs.
Myriad believes in providing the most accurate and highest quality tests for patients. From hereditary cancer to precision medicine, our tests are designed to give clinicians and patients the most accurate answer possible.
References:
Myriad Genetics, MyRisk, Precise Tumor, MyChoice, Prolaris, BRACAnalysis CDx, RiskScore, and their respective logos, are registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions. EndoPredict and the EndoPredict logo are either trademarks or registered trademarks of Eurobio Scientific.